Found 35 Carcinoma trials
A listing of Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Dynamic Nuclear Polarization-MR Spectroscopic Imaging of Hepatocellular Carcinoma Metabolism to Predict Response Following Locoregional or Systemic Therapy
Phase 2
The research study is being conducted to evaluate a new imaging technique for detecting the response of hepatocellular carcinoma (HCC) to locoregional or systemic therapy. Locoregional therapies or LRT are called Transarterial Chemoembolization or TACE, Transarterial Radioembolization or TARE and Microwave Ablation or MWA. Systemic therapies or ST are therapy …
A study evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer.
Phase 2
The research study procedures include: screening for eligibility, research blood collections, at least two research biopsies, paired research stool collections, and study treatment including evaluations and follow up visits.
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
For subjects age 18 years and older who are at an increased risk for HCC and for whom HCC surveillance is appropriate, including subjects with cirrhosis or non-cirrhotic subjects with Hepatitis B. Approximately 3,000 subjects are expected to be enrolled, comprised of approximately 2,222 ultrasound surveillance subjects and 778 subjects …
UPCC 01622 Neoadjuvant PD-1 blockade in resectable Merkel cell carcinoma
Phase 1
Please refer to Protocol Section 3.0 (Objective(s), Hypothesis(es), and Endpoint(s). Please refer to Protocol Section 3.0 (Objective(s), Hypothesis(es), and Endpoint(s). Please reer to Protocol Section 3.2 (Secondary Objective(s), Hypothesis(es), and Endpoint(s)
UPCC 18822: Randomized Pilot Clinical Trial of Neoadjuvant Pembrolizumab +/- Lenvatinib for High Risk Renal Cell Carcinoma
Please refer to Protocol Section 3.0. Please refer to Protocol Section 3.1. Please refer to Protocol Section 3.2.
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (NRG-GY031)
Phase 1
To determine the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) for combination of ATR inhibitor (M1774) and BET inhibitor (ZEN003694) in women with recurrent clear cell, endometrioid, and platinum resistant high grade serous ovarian carcinoma (HGSOC) and clear cell and endometrioid endometrial carcinoma irrespective of ARID1A status.The target …
A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Either Pembrolizumab in Combination With Chemotherapy or With Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
This is an umbrella study designed to learn more about how well different drugs work in non-small cell lung cancer. This study will test MK-4830, MK7-684, and MK-5890 with pembrolizumab and standard chemotherapy or with pembrolizumab alone in subjects with advanced NSCLC.
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 3
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may …
NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-zzxf (PHESGO) in HER2 Positive Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
This Study tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. We would like to rely on CIRB as the IRB of record for …
Fluorescence imaging of carcinoma during breast conserving surgery
Please refer to section 7. "Objectives and Endpoints" of the attached protocol. Please refer to section 7. "Objectives and Endpoints" of the attached protocol. Please refer to section 7. "Objectives and Endpoints" of the attached protocol.
